Mineralys Therapeutics

Company snapshot

At Mineralys Therapeutics we aim to redefine hypertension diagnosis, management and treatment. We are driven to break the “trial and failure” approach to hypertension management and bring a personalized approach to the management of hypertension.

• 7 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Mineralys Therapeutics. Not investment advice.

• Peer + 0 momentum

  Boehringer Ingelheim

  TA overlap score 40

Recent activity

Latest pipeline, patent, and corporate events for Mineralys Therapeutics.

1. Jun 8, 2026 Clinical update

   MLS-101-301 — Phase 3

2. Jun 8, 2026 Clinical update

   MLS-101-901 — Phase 3

3. Jun 8, 2026 Clinical update

   MLS-101-206 — Phase 2

4. Jun 8, 2026 Clinical update

   MLS-101 (Part I) — Phase 2

5. Jun 5, 2026 Clinical update

   Placebo — Phase 3

View all clinical trial activity →

• What is Mineralys Therapeutics?

  Mineralys Therapeutics is a pharma organization headquartered in Radnor, USA. It trades on NYSE under ticker MLYS. Primary therapeutic focus areas include Hypertension, Uncontrolled and Resistant Hypertension, Chronic Kidney Disease, Obstructive Sleep Apnea, Hypertension, Renal.

• Is Mineralys Therapeutics publicly traded?

  Yes. Mineralys Therapeutics is listed with ticker MLYS on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Mineralys Therapeutics develop or market?

  We link 6 drug profile(s) where Mineralys Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/mineralys-therapeutics#company-drugs.

• What are the latest developments for Mineralys Therapeutics?

  In the last 12 months our linked public records show 7 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Mineralys Therapeutics focus on?

  Mineralys Therapeutics focuses on Hypertension, Uncontrolled and Resistant Hypertension, Chronic Kidney Disease based on our analysis of their pipeline programs and drug development activities.